Lung cancer in 2014: optimizing lung cancer treatment approaches.

doi:10.1038/nrclinonc.2014.225

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Lung cancer in 2014: optimizing lung cancer treatment approaches.

Nature reviews. Clinical oncology - 1 Feb 2015

Rosell Rafael, Karachaliou Niki

Abstract excerpt

In 2014, developments in our understanding of escape signalling circuits implicated in resistance to targeted agents in patients with lung cancer have led to improvements in tackling such resistance. The potential role for PET in the management of erlotinib therapy, novel combination therapies and pharmacogenomic-driven individualization of platinum-based chemotherapy represent other key advances.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung
Share to Genes, erbB-1
Share to Lung Neoplasms
Share to Molecular Targeted Therapy
Share to Mutation
Share to Positron-Emission Tomography

Source

Open in PubMed

Identifiers

PMID: 25533943
DOI: 10.1038/nrclinonc.2014.225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics